The abnormalities in [Ca2+]i and phagocytosis of polymorphonuclear leukocytes (PMNLs) from hemodialysis (HD) patients are significantly improved by their treatment with nifedipine. However, the rapidity with which this agent induces its benefical effect and whether these derangements re-emerge after cessation of therapy are not known. We studied 5 HD patients before, during and after treatment with nifedipine. Before treatment with this agent, the basal levels of [Ca2+]i of PMNLs were markedly elevated 73 ± 3.6 nM (normal: 42 ± 0.09 nM) and their phagocytic ability markedly reduced (73 ± 7.4 µgoil/l07PMNLs/min (normal: 153 ± 3.8 µg oil/l07PMNLs/min). After 1 month of therapy, [Ca2+]i fell significantly (p < 0.01) to 53 ± 1.0 nM with further decrement of a value of 40 ± 0.9 nM by the end of 3 months of treatment. The levels of [Ca2+]i rose significantly (p < 0.01) to 61 ± 2.1 nM after 1 month of cessation of therapy and were 69 ± 2.5 nM by the end of 5 months; these values are not different from those observed before therapy. Phagocytosis improved significantly (p < 0.01) after 1 month of nifedipine therapy (107 ± 3.9 µg oil/l07 PMNLs/min) with no further improvement during the other 2 months of therapy. Only modest decrement in phagocytosis occurred during the first 3 months after cessation of nifedipine administration; marked and significant impairment (p < 0.01) in phagocytosis (80 ± 2.6 µg oil/l07 PMNLs/min) became evident at the end of the fifth month. The results show that (1) nifedipine treatment of HD patients rapidly reversed the elevation in [Ca2+]i of their PMNLs but discontinuation of the therapy is followed by rapid re-emergence of the elevation in the [Ca2+]i of the PMNLs; (2) nifedipine therapy causes rapid and significant, but only partial, improvement of phagocytosis, by PMNL of HD patients; almost 5 months is needed before a significant deterioration in phagocytosis becomes evident after stopping nifedipine treatment; (3) the elevation in [Ca2+]i of PMNLs of HD patients plays an important role in the pathogenesis of impaired phagocytosis but is only partially responsible for their derangement, and (4) the beneficial effect of nifedipine therapy on phagocytosis makes this drug a useful therapeutic tool to aid HD patients in their fight against infection. Polymorphonuclear leukocytes (PMNL) from uremic patients have elevated basal levels of cytosolic calcium ([Ca2+]) [1], reduced ATP content [1], and impaired phagocytosis [1-3]. We have previously shown that PMNLs from dialysis patients treated with nifedipine have almost normal [Ca2+]i, ATP content and phagocytosis [4]. These observations indicate that this calcium channel blocker can reverse the derangements in the metabolism and function of the PMNL of dialysis patients. However, the rapidity with which the treatment with nifedipine induces this beneficial effect, and whether the derangements in [Ca2+]i and phagocytosis of PMNL re-emerge after discontinuation of nifedipine therapy are not known. The present study examined these issues to further characterize the effect of nifedipine on PMNL function in dialysis patients.

Keywords:
Calcium channel blockers, Parathyroid hormone, Uremia
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.